Kampanjeplan Revolution Medicines, Inc.
Avansert tidsplan
Enkel graf
Om selskapet Revolution Medicines, Inc.
Revolution Medicines, Inc., компания, занимающаяся прецизионной онкологией, специализируется на разработке методов лечения, направленных на подавление мишеней, в первую очередь, в сигнальных путях RAS и mTOR. Основным кандидатом на продукт компании является RMC-4630, ингибитор SHP2, который находится в фазе 1b> F2 исследования для лечения РАС-зависимых опухолей. Его продукты на доклинической стадии включают мутантные белки RAS; SOS1, белок, который превращает RAS (OFF) в RAS (ON) в клетках; и RMC-5552, ингибитор mTORC1. Revolution Medicines, Inc. flere detaljerIPO date | 2020-02-13 |
---|---|
ISIN | US76155X1000 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 0 |
Сайт | https://www.revmed.com |
Цена ао | 38.45 |
Prisendring per dag: | 0% (38.45) |
---|---|
Prisendring per uke: | -0.7742% (38.75) |
Prisendring per måned: | -6.74% (41.23) |
Prisendring over 3 måneder: | -13.38% (44.39) |
Prisendring over seks måneder: | -12.33% (43.86) |
Prisendring per år: | +21.22% (31.72) |
Prisendring over 3 år: | +61.89% (23.75) |
Prisendring over 5 år: | +67.17% (23) |
Prisendring over 10 år: | 0% (38.45) |
Prisendring siden begynnelsen av året: | -12.09% (43.74) |
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
Institusjoner | Volum | Dele, % |
---|---|---|
Wellington Management Group, LLP | 14882086 | 9.04 |
Vanguard Group Inc | 14634391 | 8.89 |
Blackrock Inc. | 12954314 | 7.87 |
Farallon Capital Management Llc | 6736854 | 4.09 |
Nextech Invest Ag | 6296740 | 3.82 |
State Street Corporation | 6253361 | 3.8 |
BVF Inc. | 5981212 | 3.63 |
Casdin Capital, LLC | 5714775 | 3.47 |
Alphabet Inc. | 5301512 | 3.22 |
Baker Brothers Advisors, LLC | 5148657 | 3.13 |
Veileder | Stillingstittel | Betaling | Fødselsår |
---|---|---|---|
Mr. Jack Anders | Chief Financial Officer | 544.8k | 1977 (48 år) |
Mr. Walter Reiher Ph.D. | Chief Information Officer | N/A | |
Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | N/A | |
Dr. Mark A. Goldsmith Ph.D. | CEO, President & Chairman | 1.05M | 1962 (63 år) |
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development | 779k | 1961 (64 år) |
Ms. Margaret A. Horn J.D. | Chief Operating Officer | 775.6k | 1963 (62 år) |
Ms. Xiaolin Wang | Executive Vice President of Development | 604.1k | 1971 (54 år) |
Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | N/A | |
Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | N/A | 1981 (44 år) |
Ms. Jan Smith Ph.D. | Chief Scientific Officer | N/A |
Adresse: United States, Redwood City, CA , 700 Saginaw Drive - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.revmed.com
Nettsted: https://www.revmed.com